1. Overview
  2. All Stocks
  3. Evaxion Biotech A/S

Evaxion Biotech (EVAX.US) Price Target 2026/2027: 275% Upside – Rating and Stock Analysis

3,00
0,50%
Analysis framework by , founder of TradeDesk · Data: EODHD, official filings (SEC) · Updated
Price history for Evaxion Biotech (EVAX.US) – stock price at 3.00 $, August 2026
Evaxion Biotech stock price – price development 2026. Updated Aug 6, 2026.
Share this analysis:

Evaxion Biotech Price Target 2026: Analysts See 276% Upside

The average price target for Evaxion Biotech is $11.25. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 275,63% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.

Is Evaxion Biotech overvalued or undervalued?

Evaxion Biotech is currently undervalued with a gap of 275.6% relative to the price target.


The current price is $3.00, which places Evaxion Biotech in the undervalued category. The stock is considered undervalued when the price is below $10.13, and overvalued when the price exceeds $12.38.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For Evaxion Biotech, the fair value range lies between $10.13 and $12.38.


See the full price target analysis for Evaxion Biotech →

↑ Back to navigation

Analyst Ratings for Evaxion Biotech stock in 2026: Strong Buy

2 analysts cover Evaxion Biotech. There is broad agreement on a positive view — 100% recommend buying. The average price target is $11.25, which gives an upside of 275.6% from the current price.

Consensus: Strong Buy (4.50/5)
Strong Buy
1 (50%)
Buy
1 (50%)
Strong Sell Sell Hold Buy Strong Buy
4.50 out of 5 based on 2 analysts
↑ Back to navigation

About Evaxion Biotech – Bioteknologi

Evaxion Biotech A/S bruger kunstig intelligens til at udvikle nye behandlinger. De laver immunterapi mod både kræft, bakterier og virusser. Evaxion har tre forskellige AI-platforme, som de bruger til at finde de bedste kandidater: PIONEER, EDEN og RAVEN. Lige nu har Evaxion flere lægemidler i kliniske forsøg. EVX-01 og EVX-02 er to kræftmidler i fase 1/2a, og EVX-03 er længere fremme i fase 2b til forskellige kræftformer. De har også EVX-B1 og EVX-V1, som er i præklinisk fase mod infektionssygdomme. Virksomheden samarbejder også med andre for at få deres teknologier ud. Read more about the company

Key Figures for Evaxion Biotech

$ 24,6M Market cap
$ 7,5M Revenue
Bioteknologi Industry
- P/E
3.27 P/S
2.14 P/B
USA Listed on exchange
evaxion.ai Website
Sundhed Sector

What kind of stock is Evaxion Biotech?

Speculative stock

Evaxion Biotech is classified as a speculative stock.

Score Overview for Evaxion Biotech

💰 Value Score 31/100 (Low)
⭐ Quality Score 2/100 (Very Low)
🚀 Momentum Score 4/100 (Very Low)
📊 Total Score 12/100

⚠️ 5 red flags identified 4 critical

Our analysis has identified 5 potential risk factors in Evaxion Biotech that investors should be aware of.

🚨 High debt: The debt-to-equity ratio is 1,000% – the company carries considerably more debt than equity, which raises the financial risk.
⚠️ Weak financial health: The Piotroski score is only 2/9 – the company shows signs of weakened profitability, liquidity or capital structure.
🚨 Weak balance sheet (elevated risk): Altman Z2 is -15.70 – the balance sheet is measurably weaker than average. This is a risk signal based on the numbers, not a bankruptcy prediction.
🚨 Negative profit margin: The profit margin is -129.6% – the company is losing money on its operations.
🚨 Negative return on equity: ROE is -82.9% – the company is generating a negative return for shareholders.

📈 Valuation

The P/S ratio is 3.3. The P/B ratio is 2.1.

🏦 Financial Health

The Piotroski score is 2 out of 9 — weak financial health, be careful. Altman Z2 is -15.70 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 1,000.0% — high debt, which raises the risk.

🚀 Momentum & Short Interest

Short interest is 0.30% — low, the market does not expect a decline.

↑ Back to navigation

When Does Evaxion Biotech Report Earnings – Next Date: 8/20/2026

The next earnings report from Evaxion Biotech is scheduled for August 20, 2026, before the market opens. This report covers the second quarter (Q2), which ended on June 30, 2026.



↑ Back to navigation

Technical Analysis of Evaxion Biotech 2026 – Signal: Strong Sell

Overall Technical Signal: Strong Sell

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 6, 2026.

Technical analysis of Evaxion Biotech (EVAX.US) – RSI 46, MACD negative (bearish), daily candlestick chart August 2026
Evaxion Biotech technical analysis – candlestick chart with RSI and MACD. Updated Aug 6, 2026.

Trend Analysis of Evaxion Biotech A/S

Evaxion Biotech A/S is in a short-term uptrend. The price of $2.98 is 0.0% above the 20-day average ($2.98). Medium term, the picture is negative: the price is 10.0% below the 50-day average ($3.31). Long term, the stock is 29.7% below the 200-day average ($4.24), which signals a long-term downtrend.

Death Cross: The 50-day average (3.31) is below the 200-day average (4.24), which is a classic bearish signal for Evaxion Biotech A/S.

Is Evaxion Biotech A/S overbought or oversold?

Evaxion Biotech A/S has an RSI of 45.6, right in the middle of the neutral zone. There is no clear buying or selling pressure.

MACD Analysis for Evaxion Biotech A/S

Daily MACD: MACD is negative (-0.124), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is above the signal line (-0.144) by 0.020, which suggests the negative momentum is fading – a potential trend reversal could be ahead.

Weekly MACD: MACD5 is negative (-0.330), which indicates a broader bearish long-term trend. MACD5 is below the signal line (-0.233) by 0.097, which confirms continued negative long-term momentum.

Overall MACD assessment: Both the daily and weekly trend are bearish (MACD negative). However, momentum shows signs of improving on a daily basis – a potential trend reversal could be ahead, but it is not confirmed yet.

Risk Profile for Evaxion Biotech A/S

Evaxion Biotech A/S has an annual standard deviation of 113.3%, which classifies the stock as extreme risk. Only risk-tolerant investors should consider this stock, because the price swings can be very large.

Overall Technical Conclusion for Evaxion Biotech A/S

Trend: Negative. The price trades below SMA50 and SMA200.

MACD trend (zero line): Daily bearish (-0.124). Weekly bearish (-0.330).

MACD momentum (signal): Daily rising. Weekly falling.

RSI: 45.6 – neutral.

Technical signal: Strong Sell

The price is in a downtrend (below SMA50/SMA200) and MACD is negative on both a daily and weekly basis. Avoid buying and consider closing existing positions.

↑ Back to navigation

Frequently Asked Questions About Evaxion Biotech stock in 2026

Should you buy Evaxion Biotech stock now?
No, the technical signal for Evaxion Biotech is currently SELL. Evaxion Biotech trades at $3.00 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.124 with rising momentum (signal: -0.144); RSI is at 45.6 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $11.25 points to 275.6% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Evaxion Biotech stock?
The average analyst price target for Evaxion Biotech is $11.25. The current price is $3.00, which gives an upside of 275.6%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $10.13 and $12.38.
Is Evaxion Biotech a dividend stock?
No, Evaxion Biotech does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Evaxion Biotech stock?
Evaxion Biotech is rated as a stock with extreme risk. the annual standard deviation is 113.3%, which classifies the stock as extreme risk.
Is Evaxion Biotech overvalued?
No, Evaxion Biotech is considered undervalued based on the analyst price target (275.6% upside). Evaxion Biotech has the following valuation ratios: a P/S ratio of 3.3, a P/B ratio of 2.1. The analyst price target suggests that the stock is undervalued by 275.6%.
Is Evaxion Biotech overbought?
No, Evaxion Biotech is not overbought. RSI is at 45.6 (neutral zone). The technical indicators show: RSI is at 45.6 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.5% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Evaxion Biotech earnings report?
Evaxion Biotech reports its next earnings on August 20, 2026. The stock currently trades at $3.00.
Is Evaxion Biotech shorted?
Evaxion Biotech has minimal short interest of 0.30% of the free float, which is insignificant and points to very limited bearish sentiment.
Are insiders buying Evaxion Biotech stock?
There is currently no registered insider trading for Evaxion Biotech.
Is Evaxion Biotech a good stock?
Based on our total score, Evaxion Biotech is rated as a disastrous stock with a total score of 12 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 31/100, Quality: 2/100, Momentum: 4/100. In addition: analysts see 275.6% upside to the price target; technical signal: Strong Sell. Whether Evaxion Biotech is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Evaxion Biotech stock?
The outlook for Evaxion Biotech based on current data: the average analyst price target is $11.25 (+275.6%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on 8/20/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Evaxion Biotech stock moving?
Evaxion Biotech is stable right now. The technical indicators show: the price is close to the 20-day average. For the latest context, see our technical analysis, insider section and news overview above.
How high can Evaxion Biotech go?
The average analyst price target for Evaxion Biotech is $11.25, which corresponds to a potential gain of 275.6% from the current price of $3.00. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Evaxion Biotech fall?
We lack enough history to give a specific floor for Evaxion Biotech. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Evaxion Biotech do?
Evaxion Biotech A/S bruger kunstig intelligens til at udvikle nye behandlinger. De laver immunterapi mod både kræft, bakterier og virusser. Evaxion har tre forskellige AI-platforme, som de bruger til at finde de bedste kandidater: PIONEER, EDEN og RAVEN. Lige nu har Evaxion f... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Evaxion Biotech as an investment.
Did Evaxion Biotech raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Evaxion Biotech. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Evaxion Biotech making money or losing money?
No, Evaxion Biotech is currently not making money — the company is losing money with a negative profit margin of -129.6%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Evaxion Biotech go bankrupt?
The bankruptcy risk of Evaxion Biotech is rated as elevated. Altman Z2 (a model for assessing financial distress) is -15.70 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 1,000% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Evaxion Biotech have a lot of debt?
Yes, Evaxion Biotech has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,000%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
↑ Back to navigation

Explore More